The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of eribulin mesylate as first- or second-line therapy for metastatic HER2-negative breast cancer.
Mitsuhiko Iwamoto
No relevant relationships to disclose
Nayuko Sato
No relevant relationships to disclose
Risa Terasawa
No relevant relationships to disclose
Hiroya Fujioka
No relevant relationships to disclose
Yuko Takahashi
No relevant relationships to disclose
Kosei Kimura
No relevant relationships to disclose
Satoru Tanaka
No relevant relationships to disclose
Kazuhisa Uchiyama
No relevant relationships to disclose